Chronic conditions fuel demand as pneumonia market expands

It is primarily driven by the ageing population.

The total pneumonia treatment market size is expected to grow by 2036 due to rising pneumonia cases, according to a DelveInsight report.

The ageing population primarily drives the rise, as older adults are at significantly higher risk due to declining immune function and a greater prevalence of chronic comorbid conditions.

Moreover, chronic health conditions such as chronic obstructive pulmonary disease, asthma, diabetes, and cardiovascular diseases increase susceptibility to pneumonia.

The United States accounted for the largest pneumonia treatment market size in 2025, compared to other major markets, including Germany, France, Italy, Spain, the United Kingdom, and Japan.

In the United States, the annual incidence of community-acquired pneumonia is estimated at approximately 24.8 cases per 10,000 adults.

Technological innovations in molecular diagnostics, PCR-based testing, and rapid point-of-care diagnostics are enabling earlier and more accurate detection of pneumonia pathogens.

These advances improve treatment outcomes and support the development of targeted therapies, contributing significantly to market growth.